undamentalytics Newsletter
Sign in

Bridgebio Pharma, Inc. balance sheet

At the end of fiscal 2025, Bridgebio Pharma, Inc. had total assets of $936m, total liabilities of $3.01bn and shareholders' equity of −$2.09bn. It held $570m in cash against $2.01bn of debt: net debt of $1.44bn.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents3643563943773766815701,533
Receivables————25139375
Inventory—————02760
Total current assets5696438895494787217982,045
Total assets6327041,0136235469199362,162
Accounts payable99121211103688
Deferred revenue (current)——0861575
Total current liabilities6096135121144154288977
Short-term debt—1——————
Long-term debt92924314314464372,0072,630
Total debt95944314314464372,0072,630
Total liabilities1565961,8781,8681,8892,3773,0133,815
Shareholders' equity40858−870−1,255−1,354−1,468−2,087−1,662
Non-controlling interests and other (assets − liabilities − equity)6850——12———
Net debt (negative = net cash)−268−262375471−2441,4371,097
Shares outstanding124m123m147m151m175m190m195m196m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BBIO vs KNSABBIO vs BCRXBBIO vs IONSBBIO vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bridgebio Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bridgebio Pharma, Inc.